Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: Results of a large single-institution registry of a rare tumor

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2675-2682

  Gershenson, David M ^a   Bodurka, Diane C ^a   Lu, Karen H ^a   Nathan, Lisa C ^a   Milojevic, Ljiljana ^a   Wong, Kwong K ^a   Malpica, Anais ^a   Sun, Charlotte C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOW GRADE SEROUS OVARY CARCINOMA; LOW GRADE SEROUS PERITONEUM CARCINOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ADOLESCENT; AGE; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; REGISTER; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940391810     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.0873     Document Type: Article

References (30)

1. Malpica A, Deavers MT, Lu K, et al: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496-504, 2004
2. Malpica A, Deavers MT, Tornos C, et al: Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168-1174, 2007
3. Gershenson DM, Sun CC, Lu KH, et al: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361-368, 2006
4. Seidman JD, Horkayne-Szakaly I, Cosin JA, et al: Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 103:703-708, 2006
5. Schmeler KM, Sun CC, Bodurka DC, et al: Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108:510-514, 2008
6. Gershenson DM, Sun CC, Bodurka D, et al: Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol 114:48-52, 2009
7. Vang R, Shih IeM, Kurman RJ: Ovarian low-grade and high-grade serous carcinoma. Adv Anat Pathol 16:267-282, 2009
8. Schmeler KM, Sun CC, Malpica A, et al: Low-grade serous primary peritoneal carcinoma. Gynecol Oncol 121:482-486, 2011
9. Schlumbrecht MP, Sun CC, Wong KK, et al: Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer 117:3741-3749, 2011
10. Gershenson DM, Sun CC, Iyer RB, et al: Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125:661-666, 2011
11. Bodurka DC, Deavers MT, Tian C, et al: Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group study. Cancer 118:3087-3094, 2012
12. Ali RH, Kalloger SE, Santos, JL, et al: Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis. Int J Gynecol Pathol 32:529-535, 2013
13. Singer G, Kurman RJ, Chang HW, et al: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160:1223-1228, 2002
14. Singer G, Oldt R 3rd, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003
15. Shih IeM, Kurman RJ: Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518, 2004
16. Bonome T, Lee JY, Park DC, et al: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65:10602-10612, 2005
17. O'Neill CJ, Deavers MT, Malpica A, et al: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 29:1034-1041, 2005
18. Sieh W, Köbel M, Longacre TA, et al: Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14:853-862, 2013
19. Kuo KT, Guan B, Feng Y, et al: Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036-4042, 2009
20. Wong KK, Tsang YTM, Deavers MT, et al: BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177:1611-1617, 2010
21. Jones S, Wang T-L, Kurman RJ, et al: Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413-420, 2011
22. King ER, Zu Z, Tsang YT, et al: The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123:13-18, 2011
23. Grisham RN, Iyer G, Garg K, et al: BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119:548-554, 2012
24. Tsang YT, Deavers MT, Sun CC, et al: KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231:449-456, 2013
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Fredholm H, Eaker S, Frisell J, et al: Breast cancer in young women: Poor survival despite intensive treatment. PLoS One 4:e7695, 2009
27. Wilson S, Scott T, Speers C, et al: Breast cancer in young women: Have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat 147:617-629, 2014
28. Cancello G, Maisonneuve P, Rotmensz N, et al: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974-1981, 2010
29. Usach I, Blansit K, Chen LM, et al: Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol 212:188.e1-188.e6, 2015
30. Schnack TH, Sørensen RD, Nedergaard L, et al: Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology: A prospective comparative study. Gynecol Oncol 135:278-284, 2014